Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026

Jul 27, 2026
Insilico Medicine will present first in human Phase 1 data for ISM6331 at ESMO Congress 2026 in Madrid.
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026

Insilico Medicine announced in a press release that first in human Phase 1 trial data for ISM6331 has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology Congress 2026.

The congress will take place from October 23 to 27, 2026, in Madrid. The presentation will cover results from a global Phase 1 multicenter study of ISM6331 in patients with mesothelioma and other advanced solid tumors.

ISM6331 is an AI designed oral inhibitor that targets TEAD transcription factors. The study evaluates safety, tolerability, and preliminary efficacy.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.